The absence of a difference in pre-treatment and post-treatment galectin-3 levels, and the weaker relationship between galectin-3 evaluations and the risk of cardiotoxicity, suggest that galectin-3 is likely not a useful biomarker of cancer-therapy-related cardiotoxicity. Here, LGALS3 is linked to cancer.